Minerva Neurosciences reported $59.76M in Assets for its third fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Assets Change
Acadia Pharmaceuticals ACAD:US USD 602.49M 10.28M
Adma Biologics ADMA:US USD 300.56M 3.63M
ALKERMES ALKS:US USD 1.94B 15.52M
AstraZeneca AZN:LN USD 94.18B 2.39B
Biocryst Pharmaceuticals BCRX:US USD 558.59M 48.06M
Bristol Myers Squibb BMY:US USD 98.2B 2.16B
Dynavax Technologies DVAX:US USD 999.34M 23.66M
Eli Lilly And LLY:US USD 47.46B 397.9M
Esperion Therapeutics ESPR:US USD 312.83M 8.85M
GlaxoSmithKline GSK:LN GBP 60.31B 28.73B
Halozyme Therapeutics HALO:US USD 1.86B 83.15M
IONIS PHARMACEUT IONS:US USD 2.42B 34.16M
Marinus Pharmaceuticals MRNS:US USD 184.84M 75.46M
Minerva Neurosciences NERV:US USD 59.76M 5.2M
Neurocrine Biosciences NBIX:US USD 2.14B 137.7M
Novartis NOVN:VX USD 118.46B 4.45B
Novavax NVAX:US USD 2.27B 355.56M
Takeda 4502:JP JPY 14.59T 523.42B
Vanda Pharmaceuticals VNDA:US USD 621.79M 12.69M